| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Biopure Corporation |
| 11 Hurley Street, Cambridge, MA 02141 * (617) 234-6500 |
| Business Description | The company is a leading developer, manufacturer and marketer of oxygen therapeutics. Oxygen therapeutics are pharmaceuticals that are intravenously administered into the circulatory system to increase oxygen delivery to the body's tissues. |
| Offering Information Company has | |||
| Trading As | BPUR (NASNTL) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Class A Common Shares | Filing Date | 05/19/1999 |
| Domestic Shares Offered | 3,500,000 | Offer Date | 07/29/1999 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 3,500,000 | Offer Price | $12.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.840 |
| Gross Proceeds | $42,000,000 | Selling | $0.500 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | - - | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| J.P. Morgan & Co. | Lead Manager | (212) 648-0517 |
| Adams, Harkness & Hill | Co-manager | (617) 371-3705 |
| KBC Securities | Co-manager | |
| Robert W. Baird & Company | Co-manager | (414) 765-3632 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 10/31/1996 | 10/31/1997 | 10/31/1998 | 01/31/1998 | 01/31/1999 | ||
| Revenues | - | - | 0.071 | 0.000 | 1.131 | 0.054 | 0.733 |
| Income from Oper. | - | - | -22.359 | -27.108 | -30.054 | -6.964 | -7.051 |
| Net Income | - | - | -21.594 | -27.418 | -30.047 | -6.716 | -6.844 |
| E.P.S | - | - | -1.180 | -1.490 | -1.610 | -0.360 | -0.370 |
| Revenue Growth (%) | - | - | -100.00 | - | 1,257.41 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -28.63 | -6.19 | -7.01 | ||||
| Cash Flow - Inv. | -7.58 | -1.67 | -0.64 | ||||
| Cash Flow - Fin. | 28.74 | 27.74 | 16.47 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 01/31/1999 | Financial Ratios | ||||
| Total Assets | 52.56 | Current Assets | 22.23 | Current Ratio | 2.17 |
| Total Liab. | 15.72 | Current Liab. | 10.25 | Debt Ratio | 29.92% |
| Total Equity | 36.83 | Working Cap. | 11.99 | Debt to Equity Ratio | 0.43 |
| Cash | 14.89 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to repay a loan from Pharmacia & Upjohn, for capital expenditures and for general corporate purposes including costs for clinical trials for Hemopure and for pre-marketing expenditures for Hemopure and the expanded marketing efforts for Oxyglobin.. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Lebdeuf, Lamb, Greene & Macrae |
| Bank's Law Firm | Cahill Gordon & Reindel |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |